Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2011

View Archived Issues

Interim first-in-human data released on two c-Met inhibitors

Trial determines phase II doses of ixabepilone/cisplatin combination regimen in NSCLC

Halozyme discloses clinical results on new Herceptin formulation

Pulmonary Fibrosis Foundation to fund independent evaluation of Compugen's candidate for IPF

Orantinib advances through studies in NSCLC and breast cancer

U.S. universities assess CDME in model of cystinuria

Analyses focus on cardiovascular risk with naltrexone/bupropion

Novel B-raf inhibitors disclosed by Boehringer Ingelheim

Phase I study of PPI-668 commences

CSIR presents new antitumor agents

Takeda commences international phase III program for TAK-875

Lpath begins dosing in second proof-of-concept iSONEP trial

Studies confirm efficacy of Transcend-trastuzumab conjugate in HER2-positive breast cancer

Encore Therapeutics completes proof-of-concept study of ETI-511

Novel vitamin D receptor ligands synthesized at WARF

FDA clears IsoAmp HSV assay

Nile Therapeutics completes dosing in subcutaneous cenderitide trial

Phase I MultiStem study advances

Actelion Pharmaceuticals reports new prostanoid DP2 receptor antagonists

FDA approves MethylGene's IND for new study of antifungal product candidate

Lux Biosciences withdraws Luveniq MAA

Almirall and Lundbeck enter agreement to copromote escitalopram

EMA delays review of Flutiform MAA

Isotechnika receives scientific advice from EMA for voclosporin trial

Malaria vaccine RTS,S/ASO1E shows efficacy in African children

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...